Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 21933399 | HLA-DR3 (BROAD ANTIGEN) | severe sepsis | NA | NA | NA | unclassified | |
| receiver operating characteristic (roc) curves were plotted to measure the performance and discriminating threshold of dmhla-dr3, dmhla-dr7, dmhla-dr7-3, mhla-dr0, mhla-dr3 and mhla-dr7 in predicting mortality of severe sepsis. | |||||||
| 21933399 | HLA-DRB1*07 | severe sepsis | NA | NA | NA | unclassified | |
| roc curve analysis showed that dmhla-dr3 and dmhla-dr7 were reliable indicators of mortality in severe sepsis. | |||||||
| 21933399 | HLA-DR3 (BROAD ANTIGEN) | severe sepsis | NA | NA | NA | unclassified | |
| roc curve analysis showed that dmhla-dr3 and dmhla-dr7 were reliable indicators of mortality in severe sepsis. | |||||||
| 21933399 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| the change of mhla-dr over time may be a reliable predictor for mortality in patients with severe sepsis. | |||||||
| 21939530 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | positive | |
| serial increase of il-12 response and human leukocyte antigen-dr expression in severe sepsis survivors. | |||||||
| 21939530 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| we designed this prospective observational study to measure monocyte human leukocyte antigen (hla)-dr expression, plasma cytokine levels and cytokine responses on days 1 and 7 in stimulated peripheral blood mononuclear cells (pbmcs) of healthy controls and patients with severe sepsis. | |||||||
| 21939530 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | severe sepsis | NA | NA | NA | unclassified | |
| we designed this prospective observational study to measure monocyte human leukocyte antigen (hla)-dr expression, plasma cytokine levels and cytokine responses on days 1 and 7 in stimulated peripheral blood mononuclear cells (pbmcs) of healthy controls and patients with severe sepsis. | |||||||
| 21939530 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| monocyte hla-dr expression and il-12 response from pbmcs are restored in patients who survive severe sepsis. | |||||||
| 22011628 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | only_studied | |
| herein, novel perspectives regarding monocyte hla-dr assessed as a dynamic parameter in septic patients will be discussed in the context of a recently published study investigating daily evolution of monocyte hla-dr with regard to 28 day-mortality after severe sepsis. | |||||||
| 23660098 | HLA-DR (HLA-DR) | severe sepsis | NA | NA | NA | unclassified | |
| uti can decrease in the expression of treg and th17, inverse the ratio of treg/th17, decrease in the expression of il-17, il-6 and il-10, ameliorate the immune status, and improve the expression of hla-dr. uti is expected to improve the prognosis of patients with severe sepsis. | |||||||
Copyright 2024